Intriguingly, increased cytoplasmic SPTAN1 levels were detectable not only in colon carcinoma but also in Crohn’s disease and in other epithelial neoplasms, including adenocarcinomas of the stomach and small intestine, suggesting enhanced SPTAN1 levels as a nonspecific marker for neoplasia of both benign and malignant origins (Ackermann and Brieger, 2019). Here, SPTAN1 is linked to colon carcinoma.